retatrutide 2025 trial results 28.7% Weight Loss in New Study – Dr Brad Stanfield Retatrutide: The Triple Agonist That's

In practice, it seems better to tailor the choice to different patients, depending on the preference of the route of administration (oral vs injectable), the presence of intolerance or side-effects, and contraindications

This new trial built on a previous one published in NEJM last fall (I previously reviewed here) for the same indication, but the only difference was the inclusion of people with diabetes

Richard Bloomer contributes as an Academic Dean, Research Scientist, and dietary supplement expert

Men with primary hypogonadism, meaning testicular failure due to prior chemotherapy, radiation, genetic conditions such as Klinefelter syndrome, or significant orchitis, are generally poor candidates because the problem lies in the testes themselves, not the signaling above them